共 50 条
- [4] Elotuzumab, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Efficacy After Additional Follow-Up of the ELOQUENT-3 Study [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E164 - E165
- [9] Elotuzumabplus pomalidomide/dexamethasone for relapsed/refractory multiple myeloma: final overall survival from the phase 2 ELOQUENT-3 trial [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S143 - S144